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Abstract: The purpose of this study was to investigate the potential effects of combination 
therapy using magnetic nanoparticles of Fe3O4 (MNP-Fe3O4) and chemotherapeutic drugs on 
lymphoma cells. Proliferation, inhibition, and viability of Raji cells were detected by MTT 
and trypan blue exclusion. The percentage of cells undergoing apoptosis was detected by flow 
cytometry using fluorescein isothiocyanate-annexin V and propidium iodide staining. p53 and 
nuclear factor-κB (NF-κB) protein levels were measured by Western blot. The results showed 
that proliferation of Raji cells was inhibited by adriamycin or daunorubicin in a dose-and 
time-dependent manner. Cell sensitivity was improved and the 50% inhibitory concentrations 
of  adriamycin  and  daunorubicin  decreased  when  combined  with  a  MNP-Fe3O4  carrier. 
Interestingly, increased apoptosis in Raji lymphoma cells was accompanied by upregulation of 
p53 protein and downregulation of NF-κB protein. Furthermore, the combination of MNP-Fe3O4 
with adriamycin or daunorubicin increased p53 protein levels and decreased NF-κB protein 
levels more than adriamycin or daunorubicin alone, indicating that MNP-Fe3O4 could enhance 
the effect of chemotherapeutic drugs on p53 and NF-κB. Similar results for cell apoptosis 
and protein expression were not observed for the groups treated with dexamethasone ± MNP-
Fe3O4 (P . 0.05). These findings suggest a potential clinical application for MNP-Fe3O4 in 
combination with daunorubicin or adriamycin in the treatment of lymphoma.
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Introduction
Treatment of aggressive lymphoma is difficult, and the standard of care involves 
multiagent chemotherapeutic protocols incorporating adriamycin, an anthracycline 
antibiotic. Adriamycin and a similar compound, daunorubicin, originally isolated from 
streptomyces, are widely used and highly effective chemotherapeutic agents.1 It has 
recently been reported that glucocorticoids such as dexamethasone induce apoptosis 
in lymphoid cells and therefore are commonly used in chemotherapy protocols for 
lymphoid malignancies.2,3 However, this effect is of questionable clinical relevance 
because the drug doses required for significant intercalation to occur are associated with 
unacceptable side effects.4 To minimize dose-related side effects during chemotherapy, 
a promising approach is to combine conventional chemotherapy with new strategies 
to maximize the efficacy of chemotherapy by enhancing drug delivery and increasing 
the drug concentration reaching tumor cells.5
In recent years, nanomaterials, defined as particles with diameters of less than 
100 nm, have been widely applied in the fields of technology and medicine due to 
their unique physiochemical properties and tunable characteristics.6,7 Especially, it International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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has been incorporated into clinical application in therapy 
and diagnosis owing to it both improves the traditional 
drug delivery route and resists the initiative excretion of 
drugs in tumor cells.7,8 Nowadays, the most promising 
biocompatible materials are magnetic nanoparticles of iron 
oxide (MNP-Fe3O4), which are feasible to produce, easy to 
functionalize, and show satisfactory water solubilization and 
degradation in vivo.8 It has also been reported that MNP-
Fe3O4 can improve the sensitivity of anticancer drugs and 
reverse multidrug resistance, so could be used for targeted 
drug carriers with target orientation.8,9
Apoptosis is the main mechanism of cell death, and is 
mediated by a cell-intrinsic suicide program, with the   relative 
balance of pro- and antiapoptotic signaling pathways deter-
mining the fate of the cell.10 Nuclear factor-κB (NF-κB) 
transcription factors play a central role as mediators of 
immune and inflammatory responses, as well as in the control 
of cell proliferation and apoptosis.11 In addition to the well 
known function of p53 as a cell cycle regulator, the regulation 
of cell proliferation and apoptosis are also closely associated 
with regulation of normal development.5,12,13
The combination of MNP-Fe3O4 with different chemo-
therapeutics may provide new clinical options in the treatment 
of lymphoma. However, few in vitro data are available for 
the combination of MNP-Fe3O4 with other compounds, 
eg, adriamycin, daunorubicin, and dexamethasone, all of 
which are currently used in the treatment of lymphoma. The 
present study was designed to identify the cytotoxicity of this 
treatment strategy in a human Burkitt’s lymphoma cell line, 
also known as Raji cells, and to investigate possible underlying 
mechanisms by specifying a group of genes that can be altered 
significantly by the above mentioned agents.
Materials and methods
Materials
The main materials used in this study were   daunorubicin 
(Pfizer, New York, NY), adriamycin (Hisun   Phamaceutical Co, 
Zhejiang, China), dexamethasone (Xianju Pharmaceutical Co, 
Zhejiang, China), MTT (Sigma-Aldrich Co, St. Louis, MO), 
and the Annexin-V-FITC Apoptosis   Detection Kit (Peking 
University Center for Human Disease   Genomics, Beijing, 
China). MNP-Fe3O4 obtained from the State Key Laboratory 
of Bioelectronics, Southeast University,   Nanjing, China, 
were well distributed in RPMI 1640 medium (Invitrogen, 
Carlsbad, CA) containing 10% (v/v) heat-inactivated fetal 
bovine serum (HyClone, Logan, UT) by using ultrasound 
treatment to obtain an MNP-Fe3O4 colloidal suspension. 
Different concentrations of adriamycin, daunorubicin, and 
dexamethasone conjugated with 50 µM MNP-Fe3O4 were 
prepared by mechanical absorption polymerization at 4°C 
for 48 hours, as previously reported.14
cell lines and culture
The Raji lymphoma cell line was obtained from the Center 
for Human Disease Genomics of Peking University. The cells 
were cultured in RPMI 1640 medium containing 10% (v/v) 
heat-inactivated fetal bovine serum, 100 U/mL penicillin, 
and 100 µg/mL streptomycin at 37°C in a humidified 5% 
CO2 incubator, and passaged once every 2–3 days.
MTT assays
To measure the cell inhibition rate, 2 × 105/mL Raji cells were 
incubated in 96-well flat-bottomed plates (CoStar, Charlotte, 
NC). Different concentrations of adriamycin, daunorubicin, 
dexamethasone, MNP-Fe3O4, adriamycin + MNP-Fe3O4, 
daunorubicin + MNP-Fe3O4, dexamethasone + MNP-Fe3O4, 
and RPMI 1640 alone were added to these cells and cultured 
at 37°C for 6, 12, 24, 48, and 72 hours, respectively. After 
cells were added to each well with 5 µL MTT (5 mg/mL) and 
incubated at 37°C for four hours, dimethyl sulfoxide 100 µL 
was added to each well and the plates were gently shaken 
for 10 minutes. Reduction of MTT was quantified by optical 
densities (OD) at a measurement wavelength of 570 nm and 
a reference wavelength of 630 nm using a Thermo Scientific 
Varioskan Flash (Thermo Fisher Scientific, Rockford, IL). 
The cell inhibition ratio was calculated as (1-OD treated 
group/OD control group) × 100%. IC50 was defined as the 
concentration required for 50% inhibition of cell growth.
Trypan blue staining
Cell viability was tested using trypan blue staining. Briefly, 
adriamycin 0.1 µg/mL, daunorubicin 0.1 µg/mL, and 
dexamethasone 100 µg/mL alone and in combination with 
MNP-Fe3O4 50 µmol/L were incubated with Raji cells in 
24-well plates for different lengths of time. Cells were 
obtained and stained with trypan blue solution 0.4%. Finally, 
at least 200 cells were counted under the microscope.
Apoptosis assay by flow cytometric assay
Apoptosis rates were measured by flow cytometric assay.15 
After incubation in MTT assays, cells were collected at 
48 hours, washed twice with phosphate-buffered saline, 
suspended in 200 µL of binding buffer and 10 µL of Annexin 
V-FITC for 20 minutes in the dark, and thereafter 300 µL of 
binding buffer and 5 µL of propidium iodide were added to 
each sample. Analyses were done using FACSCalibur® flow International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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cytometry (Becton Dickinson, San Antonio, TX) with Cell 
Quest software.
Western blot analysis
After the experimental treatment, total protein was isolated 
and subjected to sodium dodecyl sulfate polyacrylamide 
gel electrophoresis, and then transferred to a nitrocellulose 
membrane. The blots were stained with either p53 or 
NF-κB antibodies (1:10000) overnight at 4°C, and then 
with horseradish peroxidase-conjugated goat antirabbit or 
mouse secondary antibody (1:5000) for one hour at room 
temperature. The signal was detected using the Odyssey® 
Infrared Imaging System (LI-COR Biosciences, Lincoln, 
NE), the signal received was analyzed by the Odyssey 
software, and β-actin was used as the internal control.16
statistical analysis
All experiments were repeated three times. Data were 
expressed as mean ± standard deviation and analyzed using 
the Statistical Package for Social Science (SPSS Release 
17.0; SPSS Inc, Chicago, IL). P , 0.05 was considered to 
indicate a statistically significant difference.
Results
cell growth and inhibition
Inhibition of proliferation rate in Raji cells was enhanced 
by an increase in concentration and incubation time. After 
being coincubated with MNP-Fe3O4 for 48 hours, Raji cell 
proliferation was markedly inhibited. The IC50 of adriamycin 
decreased from 12.273 µg/mL to 8.529 µg/mL and that of 
daunorubicin from 2.695 µg/mL to 1.105 µg/mL. There were 
significant differences between the adriamycin + MNP-Fe3O4-
treated group and the adriamycin-treated group (P , 0.05), 
and between the (daunorubicin + MNP-Fe3O4)-treated group 
and daunorubicin-treated group (Figure 1), but there was no 
obvious enhancement in the dexamethasone + MNP-Fe3O4-
treated group (data not shown). Similar results were found 
on trypan blue staining (see Table 1).
enhancement of apoptosis  
by adriamycin and daunorubicin
After being incubated with MNP-Fe3O4 for 48 hours, the 
proportion of apoptosis in Raji cells induced by the combina-
tion of MNP-Fe3O4 with adriamycin and with daunorubicin 
was 69.04 ± 0.38% and 55.36 ± 0.71%, respectively, and was 
increased significantly (P , 0.05) when compared with either 
adriamycin (38.37 ± 0.46%) or daunorubicin (39.49 ± 0.61%) 
used alone. However, there was no significant difference in 
the relative proportion of apoptotic cells between cells treated 
with dexamethasone + MNP-Fe3O4 and cells treated with 
dexamethasone alone (34.24 ± 0.88% versus 27.41 ± 0.23%, 
P . 0.05, Figure 2).
expression of p53 and NF-κB
Western blot assay revealed the p53 protein levels for 
the different treatment groups (Figure 3). Combination 
of MNP-Fe3O4 with either adriamycin or daunorubicin 
increased the expression of p53 protein more effectively than 
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Figure 1 Proliferation inhibitory ratio of raji cells incubated with different drugs 
with  or  without  MNP-Fe3O4.  A)  ADM  incubated  with  raji  cells  for  48  hours.   
B) DNr incubated with raji cells for 48 hours. C) either 0.1 µg/mL ADM or 0.1 µg/mL 
DNr ± 50 µmol/L MNP-Fe3O4 incubated with raji cells for different lengths of time. 
Abbreviations: MNP-Fe3O4, magnetic nanoparticles of Fe3O4; ADM, adriamycin; 
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adriamycin or daunorubicin alone. However, there was no 
significant difference in expression of p53 protein between 
cells treated with dexamethasone + MNP-Fe3O4 and cells 
treated with dexamethasone alone (P . 0.05). NF-κB pro-
tein levels were also influenced by adriamycin + MNP-Fe3O4 
and daunorubicin + MNP-Fe3O4. Compared with adriamycin 
treatment alone, MNP-Fe3O4 + adriamycin decreased 
NF-κB protein levels more effectively (P , 0.05), as 
did MNP-Fe3O4 + daunorubicin when compared with 
daunorubicin alone, suggesting that MNP-Fe3O4 can 
enhance the effects of both adriamycin and daunorubicin. 
However, p53 protein expression in Raji cells was not 
  significantly different (P . 0.05) between cells treated with 
dexamethasone ± MNP-Fe3O4.
Discussion
Resistance of lymphoma cells to chemotherapy-induced 
apoptosis remains the most significant contributor to the 
development of multidrug resistance and treatment failure. 
Moreover, the toxicity of high-dose anticancer drugs limits 
the efficacy of many chemotherapeutic agents.17 Strategies 
to reverse the resistance mechanism have been a hot topic 
in tumor therapy. The potential medical applications of 
MNP-Fe3O4 as a targeted-drug carrier with target orientation 
and sustained-release properties have been widely studied. It 
has been previously reported that MNP-Fe3O4 in combination 
with anticancer drugs could improve the efficacy of 
chemotherapeutic agents which has a synergistic effect in 
multidrug resistance.18–21
Table 1 cell viability of different drugs with or without MNP-Fe3O4 for different times (%, mean ± sD)
Group 6 hours 12 hours 24 hours 48 hours 72 hours
0.1 µg/mL ADM   92 ± 0.3 88.3 ± 0.6 82.2 ± 0.6 78.3 ± 0.6 70.8 ± 0.5
0.1 µg/mL ADM  
  + 50 µmol/L MNP-Fe3O4
91.4 ± 0.7 86.4 ± 0.7 80.3 ± 0.9 76.4 ± 0.5 66.7 ± 1.1
0.1 µg/mL DNr 92.6 ± 0.4 87.3 ± 0.6 81.1 ± 0.2 79.1 ± 0.7 69.6 ± 1.0
0.1 µg/mL DNr  
  +50 µmol/LMNP-Fe3O4
91.6 ± 0.3 85.2 ± 0.5 80.0 ± 0.7 77.4 ± 0.9 64.5 ± 2.3
100 µg/mL DeX 93.0 ± 0.5 90.1 ± 0.4 84.5 ± 0.9 79.8 ± 0.8 73.1 ± 0.8
100 µg/mL DeX  
  +50 µmol/L MNP-Fe3O4
92.4 ± 0.3 89.6 ± 0.8 85.7 ± 0.7 80.9 ± 1.0 71.5 ± 1.2
Abbreviations: MNP-Fe3O4, magnetic nanoparticles of Fe3O4; ADM, adriamycin; DNr, daunorubicin; DeX, dexamethasone.
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Figure 2 Apoptosis of raji cells incubated with different drugs for 48 hours. A) control, B) MNP-Fe3O4, C) ADM, D) ADM + MNP-Fe3O4, E) DNr, F) DNr + MNP-Fe3O4, 
G) DeX, H) DeX + MNP-Fe3O4.
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To determine if the effects of MNP-Fe3O4 combined with 
low-dose chemotherapy are different from those of high-dose 
chemotherapy, we investigated the effects of a combination 
of chemotherapeutic agents (adriamycin, daunorubicin, 
  dexamethasone) with MNP-Fe3O4 on proliferation and viabil-
ity of Raji cells in vitro. Our results show that both adriamycin 
and daunorubicin can inhibit Raji cell proliferation effec-
tively in a dose-and time-dependent manner. Furthermore, 
the effect on cell sensitivity may be further improved, and the 
IC50   values for adriamycin and daunorubicin were decreased 
when these agents were combined with (MNP-Fe3O4) as a 
carrier, so it may be inferred that MNP-Fe3O4 has synergism 
with adriamycin and daunorubicin.
Apoptosis is the consequence of a series of precisely 
regulated cellular events and is an important metabolic 
step in regulating cell numbers and growth. If apoptosis is 
blocked, cell metabolism becomes disordered, predisposing 
to development and growth of tumors.22 We have investi-
gated the cytotoxicity of MNP-Fe3O4 and chemotherapeutic 
agents to Raji cells in vitro by flow cytometry. The com-
bination of adriamycin or daunorubicin with MNP-Fe3O4 
exerted a potent cytotoxic effect on Raji cells and induced 
apoptosis, suggesting that MNP-Fe3O4 synergistically 
enhances the apoptosis induced by adriamycin or dauno-
rubicin. However, similar results were not observed for 
dexamethasone.
It is well known that p53 is an important tumor suppressor 
leading to apoptosis in response to most DNA-damaging 
agents involving primarily the intrinsic pathway,23 and that 
NF-κB also plays an important role. The NF-κB family 
of transcription factors, which regulate the expression of 
several genes, plays a critical role in numerous cellular 
processes and in tumor progression via activation of the 
NF-κB signal way.24 p53 defects and NF-κB overexpression 
are major contributing factors to drug resistance, and have 
recently been linked to reduced chemosensitivity.25 In most 
patients with lymphoma who have loss of p53 function and 
overexpression of NF-κB might help circumvent resistance 
to conventional therapies. Our results showed that either 
adriamycin or daunorubicin increased apoptosis of Raji 
cells and that this was accompanied by upregulation of p53 
protein and downregulation of NF-κB protein. Interestingly, 
in the present study, MNP-Fe3O4 combined with adriamycin 
or daunorubicin increased upregulation of p53 protein and 
downregulation of NF-κB protein, but similar results were 
not found with dexamethasone. Our findings for NF-κB 
were similar to those reported by Ottonello et al, inhibition 
of NF-kB activation decreased the production of XIAP, an 
antiapoptotic molecule, leading to uncontrolled activity of 
regulators of apoptosis (eg, caspase 3).26 Dexamethasone-
induced apoptosis in human follicular lymphoma cells with 
Bcl-XL and dominant negative caspase 9 overexpression 
has been reported,3 but this was not found for the Raji cells 
used in our study, and was not improved by combination 
with (MNP-Fe3O4), which needs to be explored further in 
the future. Overall, our results indicate that increased p53 
expression and reduction of NF-κB induced by different 
activators contribute to inhibition of cell proliferation and 
induction of apoptosis in this system.
Conclusion
Our study demonstrates that concomitant treatment with 
adriamycin or daunorubicin and MNP-Fe3O4 could enhance 
proliferation and inhibition, as well as increase adriamycin- 
and daunorubicin-induced cell apoptosis in vitro, as a result 
of regulation of various proliferative and antiapoptotic gene 
products, including p53 and NF-κB. This would promote a 
potential clinical application for MNP-Fe3O4 in combina-
tion with daunorubicin or adriamycin against lymphoma. 
However, the effect and safety of such combinations need 
to be investigated further in the clinical setting.
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